Generally, in primary tumours acquired resistance to anti-EGFR antibodies could result from compensatory mechanisms for reduced EGFR signaling [37] as well as genetic alterations in the EGFR-RAS-RAF-MEK signaling pathway or other receptor tyrosine kinases [38]. This evidence concerns the gene NTRK1 and neoplasm.